Clearmind Medicine is a clinical-stage pharmaceutical company developing psychedelic-derived drugs for mental health and addiction disorders. Its lead candidate, CMND-100, is an oral capsule containing MEAI, a synthetic, non-hallucinogenic molecule designed to produce an alcohol-like euphoric effect while reducing the desire to drink. The core idea is that MEAI can break the binge-drinking cycle by activating serotonergic pathways, rather than relying on aversion or abstinence-based mechanisms like existing AUD drugs. Clearmind is currently running a Phase I/IIa clinical trial for CMND-100 at sites including Yale School of Medicine and Johns Hopkins University. Beyond AUD, Clearmind is exploring MEAI as a potential treatment for obesity and metabolic disorders, and as an alcohol substitute consumer product. Secondary programs include a ketamine-derived compound for treatment-resistant depression and benzofuran compounds as potential MDMA substitutes for psychotherapy. Clearmind has no approved products and generates no revenue. The company funds itself through equity raises, with cash consumed by clinical trial costs and outsourced R&D. If CMND-100 eventually receives regulatory approval — requiring additional trials and FDA review over many years — Clearmind would commercialize it as a prescription drug, with royalties owed to university partners Hebrew University and Bar-Ilan University on net sales. Clearmind also holds a broader portfolio of 19 patent families covering combinations of various psychedelic compounds, largely developed in partnership with SciSparc.